Telmisartan is a specific and effective antagonist of angiotensin II receptors (AT1 type). Telmisartan with a very high affinity replaces angiotensin II at the sites of its binding on receptors of the at1 subtype, which are responsible for the activity of angiotensin II. Telmisartan does not exhibit any partial agonistic effect on the at1 receptor. Telmisartan selectively binds the AT1 receptor. the binding is permanent.
active substance: telmisartan
1 tablet contains Telmisartan 20 mg, 40 mg or 80 mg
Excipients: sodium hydroxide, meglumine, mannitol (E 421), crospovidone, magnesium stearate.
- hypersensitivity to preparation components
- pregnant women or women planning to become pregnant (see Sections "Peculiarities of use", "Application during pregnancy or lactation");
- obstructive biliary disorders;
- severe liver dysfunction
- children's age (up to 18 years old).
The simultaneous use of telmisartan and aliskiren products is contraindicated in patients with diabetes mellitus or with impaired renal function (GFR <60 ml / min / 1.73 m2) (see Sections "Pharmacological properties" and "Interaction with other medicinal products and other types of interactions") ...
Treatment of arterial hypertension.
The usual effective dose is 40 mg per day. For some patients, a daily dose of 20 mg may be sufficient. If the desired blood pressure is not reached, the dose of telmisartan can be increased to 80 mg once a day. Alternatively, telmisartan can be given in combination with the thiazide diuretics hydrochlorothiazide, which has been shown to further lower blood pressure when used with telmisartan. If it is necessary to increase the dose, it should be borne in mind that the maximum antihypertensive effect is generally achieved after 4-8 weeks from the start of treatment.
Children.
The safety and efficacy of the use of the preparation Hypotel in children (under the age of 18 years) have not been studied.
There are no reviews for this product.